Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTI-ACE2 MONOCLONAL ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2022/191162
Kind Code:
A1
Abstract:
It is required to provide a novel molecule for neutralizing the binding between coronavirus and angiotensin converting enzyme 2 (ACE2). The present invention provides a monoclonal antibody binding to ACE2.

Inventors:
KASHIWABA SHU-ICHIRO (JP)
AKIYAMA HIROTADA (JP)
OKA EIJI (JP)
OKABE YOKO (JP)
FUKUOKA MASASHI (JP)
MURAKAMI YASUFUMI (JP)
Application Number:
PCT/JP2022/009860
Publication Date:
September 15, 2022
Filing Date:
March 08, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ORDER MADE MEDICAL RES INC (JP)
International Classes:
C12N15/13; A61K39/395; A61P31/14; C07K16/40; C07K16/46
Foreign References:
CN112409488A2021-02-26
Other References:
LI WENHUI,ET AL: "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 426, no. 6965, 27 November 2003 (2003-11-27), London, pages 450 - 454, XP002342002, ISSN: 0028-0836, DOI: 10.1038/nature02145
ZHANG JIANCHENG; XIE BING; HASHIMOTO KENJI: "Current status of potential therapeutic candidates for the COVID-19 crisis", BRAIN, BEHAVIOR AND IMMUNITY., ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 87, 22 April 2020 (2020-04-22), US , pages 59 - 73, XP086197985, ISSN: 0889-1591, DOI: 10.1016/j.bbi.2020.04.046
LI SHU-REN; TANG ZI-JIAN; LI ZAI-HAN; LIU XUAN: "Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV", EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES., SPRINGER, WIESBADEN, DE, vol. 39, no. 6, 13 April 2020 (2020-04-13), DE , pages 1021 - 1026, XP037121779, ISSN: 0934-9723, DOI: 10.1007/s10096-020-03883-y
Attorney, Agent or Firm:
KOBAYASHI Hiroshi et al. (JP)
Download PDF: